Evidence map›Paper›PMID 33163949›Full record

ArticleJHEP reports : innovation in hepatology2021

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.

Giuliana Amaddeo, Raffaele Brustia, Manon Allaire, Marie Lequoy, Clémence Hollande, Hélène Regnault, Lorraine Blaise, Nathalie Ganne-Carrié, Olivier Séror, Edouard Larrey and 20 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. COVID-19: Has the Liver Been Spared?International journal of molecular sciences · 2023
    Review
  16. Review
  17. COVID-19 and the Liver: A Complex and Evolving Picture.Hepatic medicine : evidence and research · 2023
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 7 institutions in 1 country.

Giuliana AmaddeoDepartment of Hepatology, AP-HP, Hôpital Henri-Mondor, Créteil, France.
Raffaele BrustiaDepartment of Digestive and Hepato-pancreatic-biliary Surgery, AP-HP, Hôpital Henri-Mondor, Créteil, France.
Manon AllaireHepatology and Liver Transplantation Department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Paris, France.
Marie LequoyDepartment of Hepatology, AP-HP, Hôpital Saint Antoine, Paris, France.
Clémence HollandeDepartment of Hepatology, AP-HP, Hôpital Cochin, Paris, France.
Hélène RegnaultDepartment of Hepatology, AP-HP, Hôpital Henri-Mondor, Créteil, France.
Lorraine BlaiseService d'Hépatologie, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France.
Nathalie Ganne-CarriéService d'Hépatologie, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France.
Olivier SérorCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris, INSERM UMR 1138 Functional Genomics of Solid Tumors Laboratory, Paris, France.
Edouard LarreyHepatology and Liver Transplantation Department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Paris, France.
Chetana LimDigestive and Liver Transplantation Department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Paris, France.
Olivier ScattonSorbonne Université, Paris, France.
Sanaa El MouhadiDepartment of Radiology, AP-HP, Hôpital Saint Antoine, Paris, France.
Violaine OzenneDepartment of Hepatology, AP-HP, Hôpital Saint Antoine, Paris, France.
François PayeDepartment of Digestive Surgery, AP-HP, Hôpital Saint Antoine, Paris, France.
Pierre BalladurDepartment of Digestive Surgery, AP-HP, Hôpital Saint Antoine, Paris, France.
Anthony DohanDepartment of Radiology, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
Pierre-Philippe MassaultDepartment of Digestive Surgery, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
Stanislas PolDepartment of Hepatology, AP-HP, Hôpital Cochin, Paris, France.
Marco Dioguardi BurgioDepartment of Radiology, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, France.
Valérie VilgrainDepartment of Radiology, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, France.
Ailton SepulvedaDigestive and Liver Transplantation Department, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, France.
Francois CauchyDigestive and Liver Transplantation Department, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, France.
Alain LucianiParis Est Créteil University, UPEC, Créteil, France.
Daniele SommacaleParis Est Créteil University, UPEC, Créteil, France.
Vincent LeroyDepartment of Hepatology, AP-HP, Hôpital Henri-Mondor, Créteil, France.
Francoise Roudot-ThoravalDepartment of Hepatology, AP-HP, Hôpital Henri-Mondor, Créteil, France.
Mohamed BouattourDépartement d'Oncologie Digestive, AP-HP, Hôpital Beaujon, Clichy, France.
Jean-Charles NaultService d'Hépatologie, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France.
Paris Liver Cancer Group
Sorbonne Université · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Beaujon · FRHôpital Cochin · FRUniversité Paris Cité · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsPatients affected by hepatocellular carcinoma (HCC) represent a vulnerable population during the COVID-19 pandemic and may suffer from altered allocation of healthcare resources. The aim of this study was to determine the impact of the COVID-19 pandemic on the management of patients with HCC within 6 referral centres in the metropolitan area of Paris, France.

methodsWe performed a multicentre, retrospective, cross-sectional study on the management of patients with HCC during the first 6 weeks of the COVID-19 pandemic (exposed group), compared with the same period in 2019 (unexposed group). We included all patients discussed in multidisciplinary tumour board (MTB) meetings and/or patients undergoing a radiological or surgical programmed procedure during the study period, with curative or palliative intent. Endpoints were the number of patients with a modification in the treatment strategy, or a delay in decision-to-treat.

resultsAfter screening, n = 670 patients were included (n = 293 exposed to COVID, n = 377 unexposed to COVID). Fewer patients with HCC presented to the MTB in 2020 (

conclusionsIn a metropolitan area highly impacted by the COVID-19 pandemic, we observed fewer patients with HCC, and similar rates of treatment modification, but with a significantly longer treatment delay in 2020 LAY SUMMARY: During the coronavirus disease 2019 (COVID-19) pandemic era, fewer patients with hepatocellular carcinoma (HCC) presented to the multidisciplinary tumour board, especially with a first diagnosis of HCC. Patients with HCC had a treatment delay that was longer in the COVID-19 period than in 2019.

Indexed as

2019-nCoVaOR, adjusted ORBCLC, Barcelona Clinic Liver CancerCirrhosisCOVID-19EASL, European Association for the Study of LiverHCC, hepatocellular carcinomaHepatocellular carcinomaICU, intensive care unitIQR, inter-quartile rangeIR, interventional radiologyITT, intention to treatLR, liver resectionLT, liver transplantationManagementMELD, model for end-stage liver diseaseMTB, multidisciplinary tumour boardNASH, non-alcoholic steatohepatitisOR, odds ratioSIRT, selective internal radiation therapyTACE, transarterial chemoembolisation

Identifiers

PMID33163949
PMCPMC7604130
OpenAlexW3096433856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.